Behind the Bell: Conduit Pharmaceuticals

In this episode of Behind the Bell, Conduit Pharmaceuticals Chair of the Board of Directors Freda C. Lewis-Hall speaks to what she attributes the company’s success to and how being Nasdaq-listed will help it to continue to grow.

Transcript:

I think that a part of our special sauce has been the idea that we're motivated by helping patients, and they're our North Star.

Conduit Pharmaceuticals is a company that's really formed around the vision of identifying an accelerator, or pun intended, a conduit, to help compounds or medicines that are stranded or deprioritized in the industry today, and to find a way to move them forward quickly.

Listing on Nasdaq feels like an opportunity to be propelled, to be pushed forward to meet our mission, which is to change and save patients’ lives through driving forward innovative medicines, through a novel life sciences operating model.

And we couldn't be more thrilled.